INNTのチャート
INNTの企業情報
| symbol | INNT |
|---|---|
| 会社名 | Innovate Biopharmaceuticals Inc （モンスタ―・デジタル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ IT・通信（IT_Communications） |
| 概要 | 事業概要 イノベート・バイオファーマスーティカルズ(Innovate Biopharmaceuticals Inc.)(旧名：Monster Digital Inc)は臨床段階のバイオテクノロジー会社である。同社は新規自己免疫・炎症治療薬の開発に従事する。主要薬剤候補である酢酸ララジド（INN-202）はタイト・ジャンクション・レギュレーターである。他の製品にはINN-108とINN-329（セクシチン）がある。同社のINN-108はアゾ結合を通じて結合抗炎症性および免疫調節性の2つの活性部分を含む新規小分子である。同社は潰瘍性大腸炎（UC）の治療薬としてINN-108を開発する。セクレチン刺激磁気共鳴胆道膵臓造影（MRCP）は膵臓胆管系の電離放射線フリー評価である。同社はINN-202のセリアック病の第II相臨床試験を完了し、炎症性腸疾患、軽度・中等度のUCとGI希少疾患の第II相試験にあるINN-108を開発する。 モンスタ―・デジタルは米国のIT企業。主に「モンスタ―・デジタル」の商標名で電子家電、モバイル製品、アプリなどの開発・製造・販売に従事する。アクションやスポ―ツ向けカメラ・ビデオ、冒険写真カメラ、アップルiOS装置向け外部メモリ、Wi-Fiホットスポット用iCloud装置、大容量メモリなどを取り扱う。本社はカリフォルニア州シミバレ―。 Innovate Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC. |
| 本社所在地 | 8480 Honeycutt Road Suite 120 Raleigh NC 27615 USA |
| 代表者氏名 | Sandeep Laumas Sandeep Laumas |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +1 919-275-1933 |
| 設立年月日 | 40483 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | 5人 |
| url | www.innovatebiopharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/innt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -18.54641 |
| 終値（lastsale） | 5.36 |
| 時価総額（marketcap） | 138220662.32 |
| 時価総額 | 時価総額（百万ドル） 129.71080 |
| 売上高 | 売上高（百万ドル） 0.74400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 123.19936 |
| 当期純利益 | 当期純利益（百万ドル） -25.31329 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Innovate Biopharmaceuticals Inc revenues decreased from $1.1M to $0K. Net loss increased from $3.9M to $20.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $151K to $7.6M (expense) General and administrative increase from $2.7M to $8.3M (expense). |
INNTのテクニカル分析
INNTのニュース
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection 2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases 2019/10/07 10:00:00 ACI Information Group
RALEIGH, NC and TEL AVIV, ISRAEL / ACCESSWIRE / October 7, 2019 / Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases ("Innovate"), and RDD Pharma, Ltd. focused on orphan and
The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission 2019/08/16 11:33:27 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 15) AbbVie Inc (NYSE: ABBV ) Acer Therapeutics Inc (NASDAQ: ACER ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Alector Inc (NASDAQ: ALEC ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced pricing of its $6.5 million common stock offering at $1 per share) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genetic Technologies Limited (NASDAQ: GENE ) GENFIT S A/ADR (NASDAQ: GNFT ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Ironwood Pharmaceuticals, Inc.
The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results 2019/08/13 11:25:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 13) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Hemispherx BioPharma, Inc (NYSE: HEB ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB )(reacted to second quarter results) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Mallinckrodt PLC (NYSE: MNK )(was accused by Humana Inc (NYSE: HUM ) of manipulating prices of Achtar) Mersana Therapeutics Inc (NASDAQ: MRSN ) Novavax, Inc. (NASDAQ: NVAX )(reported new data from the Phase 3 trial dubbed PREPARE that evaluated its ResVax ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Pfizer Inc. (NYSE: PFE ) Plus Therapeutics Inc (NASDAQ: PSTV ) Proteostasis …
The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout 2019/08/07 11:34:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 6) Allakos Inc (NASDAQ: ALLK )(announced common stock offering) Cytokinetics, Inc. (NASDAQ: CYTK ) Insulet Corporation (NASDAQ: PODD )( reacted to forecast-beating second-quarter results) Fulgent Genetics Inc (NASDAQ: FLGT )(moved in reaction to second-quarter earnings) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 6) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM )(reacted to second-quarter results) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BIOLINERX LTD/S ADR (NASDAQ: BLRX )(reacted to second-quarter results) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) ChemoCentryx Inc (NASDAQ: CCXI )(reported below-consensus second-quarter revenues) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Endo International PLC (NASDAQ: ENDP )(reacted to second-quarter results) Equillium Inc (NASDAQ: EQ ) Evogene Ltd (NASDAQ: EVGN ) Hepion Pharmaceuticals Inc (NASDAQ: HEPA ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) MEI Pharma Inc (NASDAQ: MEIP ) Merit Medical Systems, Inc.